PledPharma
Pledpharma: On track in its clinical projects (Redeye)

2019-08-21 16:53
Most important in today’s Q2 2019 earnings report is the reiteration of previously communicated goals, suggesting patient recruitment to the POLAR studies develops as planned. We believe recent weakness of the share price most likely have been related to a growing concern of possible delays in patient recruitment, why today’s report provides reasons for a rebound of the share price. We reiterate our base case fair value of SEK 50 and expects several important news out in H2 2019 to drive investor interest of the share.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Egetis Therapeutics - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -